BioSpace News Archive

Quantabio, a leading provider of robust DNA and RNA amplification reagents for the most demanding molecular testing and life science research applications, today announced the Wisconsin State Laboratory of Hygiene has adopted its technology to improve newborn screening for Spinal Muscular Atrophy (SMA) and Severe Combined Immunodeficiency (SCID).

Bio2 Technologies, Inc., the developer of Vitrium, a unique proprietary structural and resorbable orthobiomaterial, announced the first implantation of an index patient in its randomized, multi-center, non-inferiority IDE Vitrium Cervical Interbody clinical trial.

Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today provided an update on clinical and corporate developments, including its ongoing confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD,

3-V Biosciences, a clinical-stage biotechnology company, announced today that it has changed its name to Sagimet Biosciences and closed a second tranche of its Series E financing, which now totals $25 million.

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced it will present four scientific posters and co-sponsor two posters at the 2019 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo.

MFG Chemical, a leader in specialty and custom chemical manufacturing continues to staff up for growth, this time adding two financial professionals.

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of the new EUROIMMUN Aspergillus Antigen ELISA.

71st AACC Annual Scientific Meeting & Clinical Lab Expo: Booth #1039--At the 71st AACC Annual Scientific Meeting & Clinical Lab Expo, Siemens Healthineers will feature in Booth #1039 its innovative IT solutions to combat the laboratory’s staffing challenges, limited budgets, and the increasing complexity in sample management and testing.

Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based (Polymerase Chain Reaction) DNA manufacturing for product authenticity and traceability solutions, today announced that the Company and TheraCann International Benchmark Corporation (“TheraCann”) have signed a non-binding term sheet (the “Term Sheet”) outlining agreed-upon amendments to the exclusive licensing and cooperation agreement signed March 28, 2019

Industry veteran joins at time of rapid growth for cloud-based enterprise application platform